3.66
  Price1.95%   +0.0700
(After Hours: 3.66 0 +0.00%)
Apr-20-21 08:00AM Ovid Therapeutics Announces Appointment of Professor Robert S. Langer, Sc.D., as Chair of its Scientific Advisory BoardGlobeNewswire
Apr-19-21 09:16AM Ovid Therapeutics Stops Gaboxadol Development Citing Limited Efficacy In Rare Neurological ConditionsBenzinga
08:00AM OVID Provides Update on OV101 Program and the Prioritization of its ResourcesGlobeNewswire
Mar-30-21 08:00AM Ovid Therapeutics Announces Closing of Agreement with Takeda for Global Development and Commercialization of SoticlestatGlobeNewswire
Mar-20-21 04:51AM News Flash: Analysts Just Made A Notable Upgrade To Their Ovid Therapeutics Inc. (NASDAQ:OVID) ForecastsSimply Wall St.
Mar-16-21 08:39AM Ovid Posts Larger-Than-Feared Quarterly Loss, Revenue BeatSmarterAnalyst
Mar-15-21 08:00AM Ovid Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results, Provides Corporate Update for 2021GlobeNewswire
Mar-10-21 03:44AM What Kind Of Investors Own Most Of Ovid Therapeutics Inc. (NASDAQ:OVID)?Simply Wall St.
Mar-03-21 07:46AM The Daily Biotech Pulse: KemPharm ADHD Drug Gets The Nod, MediciNova Shelves Vaccine StudyBenzinga
07:40AM 5 Top Stock Gainers for Wednesday: Michaels, Alcoa, Ovid TherapeuticsTheStreet.com
Mar-03-21 07:00AM Takeda buys epilepsy treatment rights from Ovid for up to $856 mlnReuters
07:00AM Takeda Secures Global Rights from Ovid Therapeutics to Develop and Commercialize Soticlestat for the Treatment of Children and Adults with Dravet Syndrome and Lennox-Gastaut SyndromeBusiness Wire
Jan-15-21 02:22AM Is Ovid Therapeutics (NASDAQ:OVID) In A Good Position To Deliver On Growth Plans?Simply Wall St.
Dec-16-20 07:00AM Ovid Therapeutics Announces Addition to the Nasdaq Biotechnology IndexGlobeNewswire
12:30PM Is OVID A Good Stock To Buy Right Now?Insider Monkey
Dec-02-20 11:38AM Why Ovid Therapeutics Stock Is Imploding TodayMotley Fool
11:30AM Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Ovid Therapeutics Inc. (OVID) InvestigationACCESSWIRE
Dec-02-20 09:52AM Benzinga's Top Upgrades, Downgrades For December 2, 2020Benzinga
07:35AM The Daily Biotech Pulse: Pfizer-BioNTech Vaccine Gets Temporary UK Authorization, Ovid's Trial Disappointment, Vanda Snags FDA NodBenzinga
Dec-01-20 04:52AM Ovid Therapeutics Announces Phase 3 NEPTUNE Clinical Trial of OV101 for the Treatment of Angelman Syndrome Did Not Meet Primary EndpointGlobeNewswire
Nov-25-20 08:51AM Are Options Traders Betting on a Big Move in Ovid Therapeutics (OVID) Stock?Zacks
Nov-23-20 04:01AM Ovid Therapeutics to Present at the American Epilepsy Society (AES) 2020 Virtual CongressGlobeNewswire
Nov-16-20 06:07AM These Analysts Think Ovid Therapeutics Inc.'s (NASDAQ:OVID) Sales Are Under ThreatSimply Wall St.
Nov-12-20 04:10AM Ovid Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate UpdateGlobeNewswire
Oct-14-20 07:00AM Ovid Therapeutics to Host Educational Webinar on Angelman Syndrome and OV101 Development ProgramGlobeNewswire
Oct-12-20 07:00AM Ovid Therapeutics to Present at the Child Neurology Society/International Child Neurology Association (CNS/ICNA) Virtual CongressGlobeNewswire
Oct-05-20 05:30AM Opthea to Appoint Dr Jeremy Levin as Chairman of the BoardGlobeNewswire
Sep-30-20 08:00AM Ovid Therapeutics Provides Soticlestat (OV935/TAK-935) Results from ARCADE and ENDYMION Studies Showing Seizure Reduction in Rare EpilepsiesGlobeNewswire
Sep-11-20 08:00AM Ovid Therapeutics to Present at the 2020 Cantor Fitzgerald Virtual Global Healthcare ConferenceGlobeNewswire
Aug-25-20 07:50AM Ovid Therapeutics Announces Pricing of $50 Million Offering of Common StockGlobeNewswire
07:00AM Phase 2 ELEKTRA Study of Soticlestat (TAK-935/OV935) Meets Primary Endpoint Reducing Seizure Frequency in Children with Dravet Syndrome or Lennox-Gastaut SyndromeBusiness Wire
Aug-10-20 08:00AM Ovid Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate UpdateGlobeNewswire
Aug-05-20 09:00AM Ovid Therapeutics to Participate at the William Blair Biotech Focus Conference 2020GlobeNewswire
Jul-25-20 09:10AM 3 Top Biotech Stocks to Buy NowMotley Fool
Jul-23-20 07:00AM Ovid Therapeutics and University of Connecticut Enter into Strategic Research Collaboration to Accelerate the Development of Next-Generation Genetic Therapy for Angelman SyndromeGlobeNewswire
Jul-14-20 06:35AM Is Ovid Therapeutics Stock a Buy?Motley Fool
Jul-13-20 09:00AM Ovid Therapeutics and Angelini Pharma Enter into Exclusive License Agreement to Develop, Manufacture and Commercialize OV101 for the Treatment of Angelman Syndrome in EuropePR Newswire
07:35AM How Much Of Ovid Therapeutics Inc. (NASDAQ:OVID) Do Insiders Own?Simply Wall St.
Jul-08-20 09:20AM Is Ovid Therapeutics Inc. (OVID) Going to Burn These Hedge Funds?Insider Monkey
Jun-29-20 08:00AM Ovid Therapeutics Added to Russell 2000® and Russell 3000® IndexesGlobeNewswire
Jun-25-20 08:58AM Ovid Therapeutics (OVID) Jumps: Stock Rises 12.4%Zacks
Jun-22-20 09:02AM Implied Volatility Surging for Ovid Therapeutics (OVID) Stock OptionsZacks
Jun-19-20 08:00AM Ovid Therapeutics Receives FDA Rare Pediatric Disease Designation for OV101 for the Treatment of Angelman SyndromeGlobeNewswire
Jun-11-20 08:00AM Ovid Therapeutics Announces Strategic Research Collaboration Focused on Accelerating the Development of New Treatments for Rare Neurological DiseasesGlobeNewswire
Jun-08-20 08:00AM Ovid Therapeutics Announces Multiple Presentations on the 2020 American Academy of Neurology Science Highlights PlatformGlobeNewswire
Jun-04-20 08:00AM Ovid Therapeutics Launches Pipeline Teach-In Webinar SeriesGlobeNewswire
May-12-20 08:00AM Ovid Therapeutics Announces Participation in the 2020 RBC Capital Markets Virtual Global Healthcare ConferenceGlobeNewswire
May-07-20 08:00AM Ovid Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate UpdateGlobeNewswire
07:30AM Ovid Therapeutics Announces Positive Topline Results from the Phase 2 ROCKET Trial of OV101 for the Treatment of Fragile X SyndromeGlobeNewswire
Apr-22-20 11:50AM Top Ranked Momentum Stocks to Buy for April 22ndZacks
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate which has completed Phase II clinical trial for adults with angelman syndrome; and Phase I clinical trial for adolescents with angelman syndrome or fragile X syndrome. It is also developing OV935, a drug candidate that is in Phase Ib/IIa trial for rare epileptic encephalopathies; preclinical-stage compounds for rare epilepsy disorders; and OV102, an intravenous formulation for indications in the clinical setting. The company has collaboration agreement with Takeda Pharmaceutical Company Limited. Ovid Therapeutics Inc. was founded in 2014 and is headquartered in New York, New York.
Cap:    |  Volume (24h):